Policy | August 27, 2025
Indian pharma resilient to US tariffs; Eyes US pricing reform gains: Ind-Ra
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), VASOSTRICT Injection 40 Units per 100 mL and 20 Units per 100 mL of PH Health Limited
Macitentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension
Rivaroxaban is used to treat venous thromboembolism
The acquired ANDAs represent a market opportunity of about US$ 38 million in the USA
_256_384.jpg)
Marksans Pharma gets USFDA nod for acid reflux drug
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), KENGREAL of Chiesi USA
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
Subscribe To Our Newsletter & Stay Updated
